Verrica director granted 16,000 stock options

Verrica Pharmaceuticals Inc. director Mark A. Prygocki Sr. received a grant of stock options covering 16,000 shares of common stock.

Rhea-AI Filing Summary

Verrica Pharmaceuticals Inc. director Mark A. Prygocki Sr. received a grant of stock options covering 16,000 shares of common stock. The options have an exercise price of $6.0400 per share and represent equity-based compensation rather than an open-market purchase.

These options vest in 12 equal monthly installments beginning on July 5, 2026 and will in any event be fully vested by the date of the next annual meeting of stockholders, subject to his continued service as a director through each vesting date. Following this grant, he holds 16,000 derivative securities directly.

Insider Trade Summary

Grant/Award: 16,000 shares

Grant/Award 1 txn

Insider PRYGOCKI MARK A SR

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	16,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 16,000 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date.

Key Figures

Options granted: 16,000 options Exercise price: $6.0400 per share Underlying shares: 16,000 shares +3 more

6 metrics

Options granted 16,000 options Stock Option (right to buy) grant to director

Exercise price $6.0400 per share Strike price for common stock under the options

Underlying shares 16,000 shares Common stock underlying the stock options

Post-grant derivative holdings 16,000 derivative securities Total options held following transaction

Vesting start date July 5, 2026 First monthly vesting date for the options

Expiration date June 4, 2036 Option expiration for the stock option grant

Key Terms

Stock Option (right to buy), exercise price, underlying security, vest and become exercisable, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "6.0400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

underlying security financial

"underlying_security_title: "Common Stock""

vest and become exercisable financial

"The shares underlying this option shall vest and become exercisable in 12 equal monthly installments"

annual meeting of stockholders financial

"will be fully vested on the date of the next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Verrica Pharmaceuticals (VRCA) director Mark Prygocki receive in this Form 4?

Director Mark A. Prygocki Sr. received a grant of stock options for 16,000 shares of Verrica Pharmaceuticals common stock. These options are a form of equity compensation and do not represent an open-market stock purchase or sale by the director.

What is the exercise price of the Verrica Pharmaceuticals (VRCA) stock options granted?

The granted stock options have an exercise price of $6.0400 per share. This means Prygocki can buy Verrica Pharmaceuticals common stock at $6.0400 per share once the options vest, regardless of the market price at that time.

How do the 16,000 Verrica Pharmaceuticals (VRCA) options vest for the director?

The 16,000 stock options vest in 12 equal monthly installments starting on July 5, 2026. They will be fully vested by the date of the next annual meeting of stockholders, provided Prygocki continues serving as a director through each vesting date.

Is this Verrica Pharmaceuticals (VRCA) Form 4 a stock buy or sell transaction?

This Form 4 reports an option grant, categorized as a grant or award acquisition. It is not an open-market buy or sell of common shares; instead, it reflects equity compensation in the form of stock options for future potential share purchases.

How many derivative securities does the Verrica Pharmaceuticals (VRCA) director hold after this grant?

Following this transaction, Prygocki holds 16,000 derivative securities in the form of stock options. These options give him the right to acquire up to 16,000 shares of Verrica Pharmaceuticals common stock at the stated exercise price once vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PRYGOCKI MARK A SR

(Last) (First) (Middle)

C/O VERRICA PHARMACEUTICALS INC.

44 WEST GAY STREET, SUITE 400

(Street)

WEST CHESTER PENNSYLVANIA 19380

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Verrica Pharmaceuticals Inc. [ VRCA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.04	06/05/2026		A		16,000		(1)	06/04/2036	Common Stock	16,000	$0	16,000	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date.

	/s/ Mark A. Prygocki, Sr.	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)